All topics
lifeevergreen
Research-ready episode

Why Your Blood Sugar Test Is 10 Years Late

你的血糖检查，晚了十年

What this research must answer

Insulin is the dispatcher that decides whether the energy in a meal goes to muscle or to fat. When fat spills into organs that cannot store it, the insulin signal jams, blood glucose climbs, beta cells burn out, and fatty liver, type 2 diabetes, and carotid plaque turn out to be one disease with three exits. The episode follows that machinery from a single meal to the 126 threshold, then to the frontier of GLP-1 drugs and the first MASH treatment.

胰岛素是身体里的调度员，决定每顿饭的能量去肌肉还是去脂肪。当脂肪漏进无法储存它的器官，胰岛素信号被卡住，血糖爬升，β 细胞衰竭，脂肪肝、二型糖尿病、颈动脉斑块其实是同一个病的三扇出口。影片跟着这套机器，从一顿饭走到 126 这个阈值，再走到 GLP-1 和第一个脂肪肝新药的前沿。

Opening tension

A fasting glucose of 126 turns a person into a diabetic. The number feels sudden. It is not. The machinery behind it has been failing for a decade, and the same failing machinery is quietly building plaque in the arteries and fat in the liver. This is the story of that machinery.

Opening variants
  1. ·

    The 126 threshold

    A single fasting glucose value of 126 separates normal from diabetes, but the disease begins years earlier when cells stop answering insulin.

    Selected opening: one lab number makes an invisible process concrete and questions why it feels sudden.

  2. ·

    The word everyone uses

    Insulin resistance appears in every health article, yet almost nobody can explain what insulin actually does in a healthy body.

    Best mystery opening: the gap between a famous word and an unexplained mechanism.

  3. ·

    The egg and the chicken

    Researchers still argue whether high insulin causes insulin resistance or the resistance causes high insulin. Both directions run at once, and the loop is the disease.

    Best mechanism opening: the chicken-and-egg question sets up the loop the whole film explains.

How the episode moves
  1. 01

    Why does everyone talk about insulin resistance and nobody explains it?

    A fasting glucose of 126 or an A1C of 6.5 turns a person into a diabetic. But the disease begins years earlier, when cells stop answering insulin, and the label arrives after the machinery is already failing.

    Classification and diagnosis of diabetes: https://europepmc.org/article/MED/33651569/NBK597413

    So what does insulin actually do in a healthy body?

  2. 02

    What does insulin actually do in a healthy body?

    Follow one meal. Glucose enters the blood. Insulin tells muscle and liver cells to take it out through a chain of proteins ending in the GLUT4 transporter. In a healthy person, blood glucose returns to normal in hours.

    GLUT4 and the IRS1/PI3K/Akt insulin pathway: https://www.sciencedirect.com/science/article/abs/pii/S1096719210005585

    Where does the energy go, and what does insulin have to do with fat?

  3. 03

    What does insulin have to do with fat?

    Insulin is the storage hormone. It pushes muscle and liver to store the incoming energy, and it tells fat cells to hold onto their reserves, suppressing fat breakdown. Chronically high insulin keeps that brake on, which is why hyperinsulinemia and weight gain feed each other.

    Insulin resistance and hyperinsulinemia, the egg and the chicken: https://doi.org/10.1210/clinem/dgaa886

    If insulin is the dispatcher, what exactly is LDL, and is it fat?

  4. 04

    Is LDL fat?

    The body has one lipid system with two jobs. Triglycerides are the stored energy in fat cells. Cholesterol travels inside lipoproteins, LDL and HDL. LDL delivers cholesterol to tissues, and when the artery lining leaks, into the wall, where it oxidizes and builds plaque.

    Recent insights into the cellular biology of atherosclerosis: https://pmc.ncbi.nlm.nih.gov/articles/PMC4395483/

    How does the same spill that fills the liver jam insulin signaling?

  5. 05

    How does the spill jam insulin?

    Ectopic fat inside muscle and liver cells, diacylglycerol and ceramides, blocks the insulin message at IRS1, the first relay. GLUT4 never arrives, cells stop importing glucose, and blood glucose climbs. The pancreas answers with more insulin, and high insulin pushes more storage.

    DAG-PKC and lipid-induced insulin resistance: https://pmc.ncbi.nlm.nih.gov/articles/PMC7547588/

    How long can the pancreas keep answering?

  6. 06

    How does the pancreas break?

    Beta cells are poisoned by years of high glucose and spilled fat. Accili and colleagues showed they do not simply die, they dedifferentiate and stop making insulin. UKPDS dated the decline more than a decade before diagnosis, with roughly half of beta-cell function already gone.

    Accili 2012 Cell: https://doi.org/10.1016/j.cell.2012.07.029; UKPDS 16: https://pubmed.ncbi.nlm.nih.gov/7621954/

    Why do fatty liver, diabetes, and carotid plaque arrive together?

  7. 07

    Why do the three diseases arrive together?

    They share one driver, insulin resistance and ectopic fat, so the cluster is called the metabolic syndrome. Some obese people stay metabolically healthy, and some thin people are full of misplaced fat, TOFI. The disease follows the spill, not the scale.

    The metabolic syndrome (Circulation 2003): https://www.ahajournals.org/doi/full/10.1161/01.CIR.0000088846.10655.E0; MHO review: https://doaj.org/article/07556bde60074269a81ec9cf47183a4b

    So does controlling blood sugar actually fix it?

  8. 08

    Does controlling blood sugar actually fix it?

    Partially. In an equal calorie deficit, the macronutrient label barely matters, DIETFITS found a 0.7 kilogram difference after a year. Glucose spikes and reactive dips track with hunger in some people, and exercise improves insulin sensitivity independent of weight. The sugar lever is real, but it sits inside the bigger levers of total energy, protein, and muscle.

    DIETFITS: https://pubmed.ncbi.nlm.nih.gov/29466592/; Weiss 2006: https://pubmed.ncbi.nlm.nih.gov/17093155/; OWL-CGM: https://www.sciencedirect.com/science/article/pii/S0261561426001652

    What is the frontier doing about the insulin machinery itself?

  9. 09

    What is the frontier doing about the machinery itself?

    GLP-1 drugs bypass the deaf appetite receiver and produce losses no diet trial matched, at the price of muscle, rebound, and cost. The first MASH drug was approved in 2024. The emerging model is chronic management, like blood pressure, rather than a short fix. The 126 threshold becomes legible: it is the end of a long process that starts with energy spilled into the wrong organs, and the exit signs are the liver, the beta cell, and the artery wall.

    STEP-1: https://www.nejm.org/doi/full/10.1056/NEJMoa2032183; FDA resmetirom: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease

    That is the ending: insulin resistance is the entrance, and the three diseases are three exits from the same corridor.

Story bank
  1. Opening pressure

    The 126 threshold

    One lab value converts a person into a diabetic, while the machinery behind it has been failing for a decade.

  2. Mechanism

    The GLUT4 door

    A meal becomes glucose; insulin opens the cell door through IRS1 and GLUT4; a healthy body clears it in hours.

  3. Mechanism

    The dispatcher and the brake

    Insulin sends energy to storage and suppresses fat breakdown, so chronically high insulin keeps the fat brake on.

  4. Conceptual reversal

    The lipid family

    Triglycerides store energy; cholesterol travels in LDL; LDL is a delivery system, and the trouble starts when it gets into the artery wall.

  5. Mechanism

    The IRS1 jam

    Diacylglycerol and ceramides block the insulin message at its first relay, so cells stop importing glucose.

  6. Historical turn

    The pancreas that forgot itself

    UKPDS dated beta-cell decline more than a decade before diagnosis; Accili showed the cells dedifferentiate rather than simply die.

  7. Conceptual reversal

    Five indicators, one engine

    The metabolic syndrome clusters waist fat, triglycerides, HDL, blood pressure, and glucose, and MHO and TOFI prove the disease follows the spill, not the scale.

  8. Application decision

    The sugar lever and its limits

    DIETFITS found a 0.7 kilogram difference after a year; spikes track hunger in some people, but the calorie and muscle levers dominate.

  9. Frontier and return

    The machinery gets its own drugs

    GLP-1 bypasses the deaf appetite receiver, and the first MASH drug arrived in 2024; the model is chronic management, like blood pressure.

How the system works
Input
A meal raising glucose, insulin release, ectopic fat spilling into liver, muscle, and pancreas, and LDL crossing a leaky artery lining.
Transformation
Insulin dispatches energy to storage; ectopic lipids jam the IRS1 signal, beta cells dedifferentiate under gluco- and lipotoxicity, and oxidized LDL builds plaque.
Output
A rising metabolic-syndrome dashboard, the 126 threshold, and cardiovascular risk.
Limit
The cluster is reversible early and partially later, but every lever, diet, drug, or monitor, sits inside a dominant calorie and muscle equation.
Mechanism cards

  1. Hepatic de novo lipogenesis

    Input
    Fructose and surplus carbohydrate reaching the liver.
    Transformation
    The liver converts fructose preferentially into new triglycerides, outpacing glucose-driven synthesis.
    Output
    Liver fat accumulation — the MASLD pathway — without any alcohol.
    Limit
    DNL is one contributor among many; total energy surplus and adipose spillover matter as much.
    Evidence
    Geidl-Flueck & Gerber 2023 — fructose drives de novo lipogenesis: https://pubmed.ncbi.nlm.nih.gov/36753292/

  2. Lipid spillover and lipotoxicity

    Input
    Ectopic fatty acids in muscle, pancreas, and perivascular tissue.
    Transformation
    Fatty-acid intermediates disrupt insulin signaling and provoke inflammation in organs with no storage capacity.
    Output
    Insulin resistance, beta-cell stress, and arterial-wall inflammation.
    Limit
    Not every fat person has spillover; storage location and adipose function decide individual risk.
    Evidence
    JACC 2026 — Rethinking obesity through the lens of lipid spillover: https://www.jacc.org/doi/full/10.1016/j.jacbts.2026.101532

  3. Visceral and liver fat to carotid plaque

    Input
    Visceral adiposity, hepatic fat, and perivascular adipose tissue.
    Transformation
    Imaging cohorts show visceral and liver fat tracking with carotid intima-media thickness and plaque burden; perivascular fat adds local inflammatory signaling.
    Output
    Measurable atherosclerosis in people whose BMI may look normal.
    Limit
    Associations are strong and graded but not proof that removing fat alone reverses plaque.
    Evidence
    Communications Medicine 2025 — visceral and hepatic fat as determinants of carotid atherosclerosis: https://link.springer.com/article/10.1038/s43856-025-01123-y

  4. GLP-1 pharmacology

    Input
    An incretin signal that normally rises after eating.
    Transformation
    Semaglutide mimics GLP-1, turning hunger down at its source; STEP-1 averaged 17.3 kg lost over 68 weeks.
    Output
    Weight loss larger than any diet trial.
    Limit
    A meaningful share of the loss is lean mass unless protein and training are added; weight returns on discontinuation; access is priced.
    Evidence
    STEP-1 (NEJM 2021): https://www.nejm.org/doi/full/10.1056/NEJMoa2032183

  5. The insulin-glucose door

    Input
    Glucose entering the blood after a meal, plus insulin released by the pancreas.
    Transformation
    Insulin signals muscle and liver cells through an IRS1-PI3K-Akt chain; the GLUT4 transporter moves to the cell surface and imports glucose.
    Output
    Blood glucose returns to normal; surplus is stored as glycogen or fat.
    Limit
    Ectopic fat inside cells, especially diacylglycerol and ceramides, blocks IRS1 so GLUT4 never arrives and glucose stays high.
    Evidence
    GLUT4 and the IRS1/PI3K/Akt insulin pathway: https://www.sciencedirect.com/science/article/abs/pii/S1096719210005585; DAG-PKC and lipid-induced insulin resistance: https://pmc.ncbi.nlm.nih.gov/articles/PMC7547588/

  6. Beta-cell burnout

    Input
    Years of high glucose and fat spilling into the pancreas.
    Transformation
    Glucotoxicity and lipotoxicity push beta cells to lose their identity and stop secreting insulin; Accili and colleagues showed the mechanism is dedifferentiation more than cell death.
    Output
    Insulin secretion falls, blood glucose climbs, and diabetes is diagnosed.
    Limit
    Some loss is reversible if caught early, but UKPDS traced the decline starting more than a decade before diagnosis, with about half of beta-cell function already gone by then.
    Evidence
    Accili et al. 2012 — Pancreatic beta cell dedifferentiation as a mechanism of diabetic beta cell failure: https://doi.org/10.1016/j.cell.2012.07.029; UKPDS 16 — type 2 diabetes as a progressive disease: https://pubmed.ncbi.nlm.nih.gov/7621954/

  7. Plaque anatomy

    Input
    LDL crossing a leaky artery lining into the wall.
    Transformation
    LDL oxidizes; macrophages swallow it and become foam cells; a fibrous cap forms around a lipid-rich necrotic core.
    Output
    A plaque that can grow silently, thin its cap, tear, and clot.
    Limit
    Heavy calcification marks stable plaques; the dangerous ones are soft and inflamed. ApoB tracks risk better than LDL-C.
    Evidence
    Cellular biology of atherosclerosis: https://pmc.ncbi.nlm.nih.gov/articles/PMC4395483/; Molecular pathways of vulnerable carotid plaques: https://pubmed.ncbi.nlm.nih.gov/38673936/

  8. Insulin as the storage hormone

    Input
    A meal raising blood glucose and triggering insulin release.
    Transformation
    Insulin tells muscle and liver to store the incoming energy and tells fat cells to hold onto what they have, suppressing fat breakdown for hours.
    Output
    The body prioritizes storage and spends glucose before it taps fat.
    Limit
    Chronically high insulin keeps the fat brake on and pushes more energy into storage, which is why hyperinsulinemia and weight gain feed each other.
    Evidence
    Insulin resistance and hyperinsulinemia, the egg and the chicken (JCEM 2021): https://doi.org/10.1210/clinem/dgaa886

  9. The lipid family

    Input
    Triglycerides, cholesterol, and the lipoproteins that carry them.
    Transformation
    Triglycerides are the energy-storage fat in adipocytes; cholesterol travels inside LDL and HDL particles; LDL delivers it to tissues and, when the artery lining leaks, into the wall.
    Output
    One lipid system with two different jobs, storage and transport.
    Limit
    LDL is a delivery system, not a synonym for body fat; the trouble starts when it accumulates in the wall and oxidizes.
    Evidence
    Recent insights into the cellular biology of atherosclerosis: https://pmc.ncbi.nlm.nih.gov/articles/PMC4395483/

  10. The IRS1 jam

    Input
    Insulin binding its receptor on muscle and liver cells.
    Transformation
    The signal passes through IRS1 into the PI3K-Akt chain toward GLUT4; ectopic lipids, diacylglycerol and ceramides, block IRS1 so the chain dies early.
    Output
    GLUT4 stays inside, cells stop importing glucose, and blood glucose climbs.
    Limit
    The same lipid jam also drives inflammation, so resistance and lipotoxicity reinforce each other.
    Evidence
    DAG-PKC and lipid-induced insulin resistance: https://pmc.ncbi.nlm.nih.gov/articles/PMC7547588/

  11. The metabolic syndrome cluster

    Input
    Waist fat, high triglycerides, low HDL, high blood pressure, high fasting glucose.
    Transformation
    Five indicators share one driver, insulin resistance and ectopic fat, so they arrive together across decades.
    Output
    A cluster diagnosis that predicts diabetes and cardiovascular disease better than any single marker.
    Limit
    The cluster hides behind normal-looking individual numbers; each marker alone can stay inside the normal range.
    Evidence
    The metabolic syndrome (Circulation 2003): https://www.ahajournals.org/doi/full/10.1161/01.CIR.0000088846.10655.E0

  12. Exercise and insulin sensitivity

    Input
    Regular physical activity, aerobic or resistance.
    Transformation
    Muscle contraction imports glucose through its own pathway and improves insulin action independent of weight loss.
    Output
    Better glucose tolerance and lower diabetes risk even when body weight barely changes.
    Limit
    Exercise improves the system but does not cancel a sustained calorie surplus or a toxic food environment.
    Evidence
    Weiss et al. 2006 — exercise energy expenditure and insulin action: https://pubmed.ncbi.nlm.nih.gov/17093155/

  13. Glucose spikes and appetite

    Input
    Rapid glucose rises after refined carbohydrates and sugary drinks.
    Transformation
    Large spikes are followed by reactive dips, and the dips track with hunger in some people; eating order and composition can blunt the spike.
    Output
    A testable lever for appetite and cravings, with individual variability.
    Limit
    Evidence for glucose-monitor-driven weight loss outside diabetes is still early; the calorie deficit remains the dominant lever.
    Evidence
    Continuous glucose monitoring for weight loss maintenance feasibility trial: https://www.sciencedirect.com/science/article/pii/S0261561426001652
Where this changes a real decision

SignalWaist circumference, fasting glucose, triglycerides, HDL, blood pressure, and liver fat on imaging.

Decision ownerThe clinician, the patient, and increasingly the payer for GLP-1 and the first MASH drug.

ThresholdWhether the cluster crosses metabolic-syndrome criteria; whether glucose or fibrosis reaches treatment thresholds; whether cost and coverage make the tool accessible.

ActionScreen the cluster early, prescribe lifestyle with protein and muscle, and add GLP-1 or MASH drugs where the evidence and price justify it.

ConsequenceEarly detection slows the ten-year decline toward diabetes, and treating the cluster reduces the shared cardiovascular and liver risk at once.

Application chains

  1. The early screening decision

    SignalA widening waist, rising fasting glucose and triglycerides, falling HDL, and liver fat on imaging.

    Decision ownerThe primary-care clinician and the patient.

    ActionScreen the cluster before any single marker crosses its threshold, and start lifestyle with protein and muscle.

    ConsequenceCatching the cluster early slows the ten-year decline toward diabetes and reduces shared cardiovascular and liver risk at once.

  2. The drug decision

    SignalMetabolic syndrome with elevated glucose, fibrosis-stage MASLD, or repeated lifestyle failure.

    Decision ownerThe clinician, payer, and patient.

    ActionPrescribe GLP-1 with muscle protection, or the first MASH drug for advanced fibrosis, and plan for long-term management.

    ConsequenceThe machinery can be treated directly, but muscle loss, rebound, and price move the fight to access and adherence.

  3. The measurement decision

    SignalA person with large glucose swings or unexplained hunger after meals.

    Decision ownerThe individual, guided by a clinician.

    ActionUse glucose monitoring or eating-order changes as a behavioral lever within a calorie and protein plan.

    ConsequenceReal-time feedback can lower intake, but the evidence outside diabetes is early, and the deficit still dominates.

The limit this episode must keep

The insulin story is strong, not total. Some obese people stay metabolically healthy, and some thin people carry the TOFI pattern, so the disease follows the spill, not the scale. In an equal calorie deficit, the macronutrient label barely matters, so sugar is a lever inside the bigger levers of total energy, protein, and muscle. Glucose-monitor weight loss outside diabetes still has thin evidence. Blaming sugar alone is wrong; declaring insulin resistance irreversible is equally wrong.

Key sources